Trial · NCT07894120
Clinical Trial Protocol for the Effectiveness and Safety of Radiofrequency Skin Therapy Equipment in Improving Facial Skin Wrinkles
NCT07894120, Not applicable, Completed, Peking University Third Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Clinical Trial Protocol for the Effectiveness and Safety of Radiofrequency Skin Therapy Equipment in Improving Facial Skin Wrinkles. Trials, record NCT07894120. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07894120
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical Trial Protocol for the Effectiveness and Safety of Radiofrequency Skin Therapy Equipment in Improving Facial Skin Wrinkles
- NCT number
- NCT07894120
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 278 participants, actual
- Lead sponsor
- Peking University Third Hospital
- Conditions
- Improve Facial Wrinkles
- Interventions
Radiofrequency skin therapy equipment developed and produced by ReFumei (Hunan) Technology Co., Ltd. improves facial wrinkles, The control group subjects used the radiofrequency therapy device produced by Israel Flyton Laser Co., Ltd. to improve facial wrinkles
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Main effectiveness indicators | 90 days after treatment | Overall clinical efficacy rate，Using the Fitzpatrick Skin Wrinkle and Elasticity Rating Scale, a four level evaluation was conducted on the improvement rate of wrinkles before and after treatment, based on the pre-treatment baseline: significant improvement, moderate improvement, mild improvement, and no improvement. ① Significant improvement: Wrinkle improvement rate\>75%; ② Moderate improvement: The wrinkle improvement rate is between 51% and 75%; ③ Mild improvement: The wrinkle improvement rate is between 25% and 50%; ④ No improvement: Wrinkle improvement rate\<25%. Overall clinical efficacy rate=(number of significantly improved cases+number of moderately improved cases+number of mildly improved cases)/total cases. |
| Primary | Main safety indicators | Before and immediately after treatment | Measure the respiratory frequency of the subject using a pulmonary function meter，in beats per minute |
| Primary | Main safety indicators | Before intervention, during treatment, and 90 days after treatment | Adverse event incidence rate |
| Primary | Secondary effectiveness indicators | On the 7th, 30th, and 90th day after treatment | VISIA Facial Rating |
| Primary | Secondary effectiveness indicators | Immediately after treatment | Visual Analogue Scale |
| Primary | Secondary effectiveness indicators | Immediately after treatment, 7 days after treatment | Skin reaction score |
| Primary | Secondary effectiveness indicators | 90 days after treatment | Using a satisfaction rating scale，Calculate the proportion of satisfied patients |
| Primary | Main safety indicators | Before and immediately after treatment | Using a thermometer to measure the patient's body temperature，Body temperature unit Celsius |
| Primary | Main safety indicators | Before and immediately after treatment | Measure the subject's pulse using a pulse oximeter, in beats per minute |
| Primary | Main safety indicators | Before and immediately after treatment | Measure the subject's blood pressure using a sphygmomanometer, in mmHg |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07894120
GET https://conductscience.org/api/trials/v1/NCT07894120/registered